Company record · RNAZ
TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc.'s interim chief financial officer on the record is John Tattory, effective September 9, 2026, per the filing record.
Tracked changes
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.